Microbiome therapeutics – the pipeline for C. difficile infection

In recent years, the human microbiome has become a burgeoning area of research and this promise has translated to microbiome-based therapeutics. The market for these innovations is rapidly growing, with the ability to modulate the microbiome or its associated host interactions offering new therapeutic strategies and a fresh approach to drug discovery for several conditions.

Despite no microbiome-based biotherapeutics or diagnostic products being approved for use to-date, it has been estimated that the human microbiome market could be worth US$2.2 billion by 2025 – demonstrating the opportunities and potential this area holds [1].

With regards to Clostridium difficile, fecal microbial transplant (FMT) has been demonstrated to be an effective treatment for recurrent C. difficile infections (rCDIs), opening the door to fecal microbiota-based therapies for this disease, which would have all the benefits of FMT but with a tested and consistent safety profile [2].

Here, we take a look at the key microbiome therapeutics currently in the clinical pipeline for rCDI and their prospects for the treatment of this disease in the future.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment